drugset
Drugs / NNI-362
last change Aug 2025 re-read 3 minutes ago

NNI-362

Small molecule

Trials 0

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Comparator or background therapy1 trial
Phase 1 NCT04074837 Comparator Aug 2019 → Jul 2021 Alzheimer disease Neuronascent, Inc. Completed No outcome recorded

Press releases naming this drug 11 releases

DateIssuerRelease
2025-08-19 Neuronascent, Inc. Neuronascent Announces Progress for Lead Candidate NNI-362: Publication of Phase 1a Clinical Trial Results and FDA Grants Waiver of Fee for Canine Cognitive Disorder 2025 Submissions neuronascent.com ↗
2023-08-22 Neuronascent, Inc. Neuronascent Announces NIA Grant Award for NNI-362 to Reach Phase 2 Clinical Trials for Mild to Moderate Alzheimer’s Disease neuronascent.com ↗
2023-06-28 Neuronascent, Inc. Neuronascent to Present New Parkinson’s Model Data at AAIC 2023 for the Alzheimer’s Disease Investigational Therapy, NNI-362 neuronascent.com ↗
2022-11-08 Neuronascent, Inc. Neuronascent to Present Further NNI-362 Phase1a Data at CTAD 2022 for Alzheimer’s Disease neuronascent.com ↗
2022-04-12 Neuronascent, Inc. NNI-362 Is Safe, Lowers Alzheimer’s Biomarker in Older, Healthy Adults neuronascent.com ↗
2022-03-30 Neuronascent, Inc. Neuronascent Releases Further Positive Results of NNI-362 in A Randomized Phase 1a Trial for Alzheimer’s Disease neuronascent.com ↗
2021-11-01 Neuronascent, Inc. NeuroNascent Presents Results of Phase 1a Human Safety Clinical Trial of NNI-362 at the CTAD conference in Boston, November 9-12. neuronascent.com ↗
2021-09-29 Neuronascent, Inc. Neuronascent Releases Positive Topline Phase 1a Safety Results of NNI-362 for Alzheimer’s Disease. neuronascent.com ↗
2021-01-20 Neuronascent, Inc. Neuronascent Announces Publication of Pre-clinical Results of Alzheimer’s Disease Clinical Candidate, NNI-362 in SCR&T Journal. neuronascent.com ↗
2021-01-01 Neuronascent, Inc. Stem Cell Research & Therapy Publishes “Novel Pharmacotherapy: NNI-362, an Allosteric p70S6 Kinase Stimulator, Reverses Cognitive and Neural Regenerative Deficits in Models of Aging and Disease.” neuronascent.com ↗
2019-05-07 Neuronascent, Inc. Neuronascent Announces FDA Clearance of IND Application for NNI-362 an Aging Therapy to Treat Alzheimer’s Disease neuronascent.com ↗

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as NNI-362 ClinicalTrials.gov intervention name — accepted as the source's own label NCT04074837 ↗
Action Activate “NNI-362, an allosteric p70S6 kinase stimulator” PMID 33436007 ↗ Jan 2021
Modality Small molecule “NNI-362 small molecule in liquid suspension.” NCT04074837 ↗
Route Oral “Oral NNI-362” NCT04074837 ↗